UCB announced that the final analysis of an open-label extension (OLE) study on Fintepla (fenfluramine) in Lennox-Gastaut syndrome (LGS) was published in the Epilepsy and Behavior journal. This follows previous presentations at a medical conference and highlights the long-term sustained benefit and lack of new or unexpected safety signals, which we view as supportive of Fintepla's benefit in this patient population. For reference, Fintepla is one of UCB's 5 growth drivers, and we estimate peak s...
Weekly progress on share repurchase program to cover share plans and reduce capital Press Release Weekly progress on share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), October 14, 2025 dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 13, 2025 its intention to repurchase ordinary shares with an aggregate market value of €1 billion and reduce its issued capital, starting with an initial €500 million. On April 1, 2025, the company commenced a program to repurchase ordinary shares for a total ...
UCB announced the publication of results from a multicenter retrospective chart review study of pyrimidine nucleo(s)(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d) in Neurology, which are in line with previous reports of the positive outcomes on survival and functional outcomes presented at a medical conference earlier this year. Note that TK2d is an ultra-rare genetic mitochondrial disease with no approved therapies, and has a prevalence of 1.64 per 1m people. Doxecitine an...
Ageas: AG Real Estate looking to reduce exposure to Interparking, lower capital charges. Air France-KLM: 3Q25 a bit light? ASML: Preview 3Q25, riding the AI wave. Barco: Preview 3Q25, self-help offsets macro headwind. D'Ieteren: Belron starts to roll out static mobile recalibration. Euronext: September's seasonal recovery. Tessenderlo More focus on capital allocation and returns. TomTom: Preview 3Q25, Cost cutting offsets slow markets. Umicore: Gold inventory sale-and-lease-back
Weekly progress on share repurchase program to cover share plans and reduce capital Press Release Weekly progress on share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), October 7, 2025 dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 13, 2025 its intention to repurchase ordinary shares with an aggregate market value of €1 billion and reduce its issued capital, starting with an initial €500 million. On April 1, 2025, the company commenced a program to repurchase ordinary shares for a total a...
Two Directors at UCB SA sold after exercising options/sold 8,000 shares at between 248.275EUR and 252.680EUR. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the compan...
According to media reports, Paul Stoffels, Galapagos' previous CEO, has assembled a group of investors to bid for the company's cell therapy business. After joining Galapagos in 2022, Paul Stoffels pivoted the company towards cell therapies and focussed the company's efforts on de-centralised CAR-T manufacturing as a way to broaden access to such treatments. Following his resignation earlier this year, he now has placed a non-binding offer for the cell therapy business which is under strategic r...
Galapagos announced that it has received a limited number of non-binding offers from consortia, predominantly comprised of financial investors, to acquire the cell therapy business. The deadline for potential bidders to put forward binding, fully-financed, offers is in the coming weeks. The company will make an announcement on the outcome of the review of strategic alternatives for the cell therapy business no later than its 3Q25 update on 5 November 2025. € 37 TP and ACCUMULATE reiterated.
Galapagos Provides Update on Strategic Alternatives for Its Cell Therapy Business Mechelen, Belgium; October 1, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and its Board of Directors today issued the following statement: On May 13, 2025, Galapagos announced that its Board of Directors (the “Board”) had decided to explore all strategic alternatives for its cell therapy business (the “Cell Therapy Business”), including a potential divestiture of the Cell Therapy Business, with the goal of preserving shareholder value. As part of its review of strategic alternatives, over ...
Galapagos geeft update over strategische alternatieven voor haar celtherapieactiviteiten Mechelen, België; 1 oktober 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) en haar Raad van Bestuur hebben vandaag de volgende verklaring uitgegeven: Op 13 mei 2025 kondigde Galapagos aan dat haar Raad van Bestuur (de “Raad”) had besloten om alle strategische alternatieven voor haar celtherapieactiviteiten (de “Celtherapieactiviteiten”) te verkennen, met inbegrip van een mogelijke verkoop van de Celtherapieactiviteiten, met als doel het waarborgen van aandeelhouderswaarde. Als onderdeel...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.